Febrile infection-related epilepsy syndrome

Febrile infection-related epilepsy syndrome (FIRES) is an epilepsy syndrome in which new-onset refractory status epilepticus (NORSE) is preceded by febrile illness 24 hours to 2 weeks prior to the onset of seizures. The term was previously used for a paediatric syndrome but was redefined to include all ages.[1]

Febrile infection-related epilepsy syndrome
Other namesAcute encephalitis with refractory, repetitive partial seizures (AERRPS), new-onset refractory status epilepticus (NORSE), devastating epilepsy in school-aged children (DESC).
SymptomsPrior febrile illness with or without upper respiratory tract infection and/or gastroenteritis. Convulsive seizures within two weeks of fever.
ComplicationsSevere intractable epilepsy, status epilepticus
Usual onsetAges 3-15
DurationAcute phase lasts 1-12 weeks. Chronic phase is lifelong pharmacoresistent epilepsy and intellectual disability.
CausesUnknown, preceded by unspecified febrile illness
PrognosisPoor, 82% of patients experience some level of permanent intellectual disability ranging from mild to vegetative state.
Frequency1 in 1,000,000
Deaths30% mortality rate

FIRES was previously to refer to this syndrome in children aged three to fifteen years old. A healthy child that may have been ill in the last few days or with a lingering fever goes into a state of continuous seizures. The seizures are resistant to seizure medications and treatments, though barbiturates may be administered.[2] Medical diagnostic tests may initially return no clear diagnosis and may not detect any obvious swelling on the brain. The syndrome is very rare: it may only affect 1 in 1,000,000 children.[3]

Febrile infection-related epilepsy syndrome (FIRES) is an infrequent, severe, and potentially deadly childhood epileptic syndrome.[4] It can be described as potentially deadly or infrequent catastrophic epileptic encephalopathy.[4] The characteristics of FIRES are repeated seizures, and febrile illness but no signs of infections.[5] Febrile infection-related epilepsy syndrome (FIRES) was introduced by van Baalen and colleagues in 2010. [6] FIRES also points to the severe clinical progression often consequential in global brain atrophy and poor outcome.[6] NORSE describes a condition in which a healthy person who has not had seizures before, begins having seizures.[6] The clinical progression of FIRES is frequently consequential in global brain atrophy, the outcome of that is very poor.[4] Initial mortality and morbidity are significant, and most survivors are left with drug-resistant multifocal epilepsy and variable degrees of intellectual disability.[4] A fever in an otherwise healthy child is supposedly a risk factor for Febrile Infection-Related Epilepsy Syndrome frequent.[4] The consequence of FIRES is unfortunate, the death rate of up to 30%. FIRES is an immune disorder triggered by an infection.[4] Between 10 and 11.7% of patients die during the acute phase of FIRES either due to obstinate status epilepticus or complications of treatment, including sepsis.[4]

It can be assumed that FIRES is associated with metabolic problems, infection, and autoimmune disorders.[7] Affected patients have an unremarkable neurological history and, in close relation with a febrile illness (mainly upper respiratory tract infection or, less frequently, gastroenteritis), abruptly develop several seizures. Electroencephalography (EEG) abnormalities in the hyperacute phase of FIRES.[7] FIRES is characterized by the onset of fever between 24 hours and 2 weeks before the onset of SE and the fever has usually resolved when the seizures start.[7] In the acute phase, SE is particularly obstinate to treatment and can last for many weeks.[7] This is followed by a chronic phase of intractable epilepsy, usually accompanied by cognitive impairment of variable severity.[7] An inflammation can results in acetonemia, raises of fatty acids, inflection of glycemia, and comparative caloric limit.[7]


Signs and symptoms

FIRES start with a febrile illness up to two weeks before seizure onset.[8] The clinical characteristic of FIRES is the onset of fever before the onset of SE.[8] The fever gradually decreases and then subsides when the seizures occurred.[8] SE is obstinate to treatment and continued for a few weeks.[8] The chronic phase of uncontrollable epilepsy leads to various degree of cognitive impairments.[8] These seizures damage the frontal lobe's cognitive brain function such as memory and sensory abilities.[2] behavioral disorders, memory issues, sensory changes, and possibly death. Children continue to have seizures throughout their lives.[2] Prolonged status epilepticus triggered motor disability in the patients with FIRES.[9] The severity of symptoms vary person to person, there are few symptoms that can be seen in a person with FIRES.[4] The severity of symptoms vary person to person, there are few symptoms that can be seen in a person with FIRES.[4] Before any neurological symptoms, fever can be observed in many cases, afterward seizures developed.[10] Cognitive ability can be impaired by repeated and continuous seizures.[11] The damage mainly occurred in frontal and temporal lobe regions and resulted in learning disorder, memory function impairment, and motor function impairment.[11]

  • Autoimmunity
  • Behavioral abnormality
  • Cough
  • Developmental regression
  • Focal-onset seizure
  • Headache
  • Lethargy
  • Pain in muscle
  • Sinus inflammation [4]
  • EEG abnormality
  • Fever
  • Myalgia[7]

Cause

The cause of FIRES is not known.[5] The reasons behind Febrile Infection-Related Epilepsy Syndrome are unidentified.[7] There are some common clinical symptoms, such as onset after a nonspecific febrile illness, gastrointestinal illness, or upper respiratory infection.[5] This prior illness is often cleared 1–14 days prior to the patient's first seizures.[5] It can be assumed that it is associated with metabolic problems, infection, and autoimmune disorders.[7] There are theories of an immunological source, a genetic predisposition, and an inflammation-mediated process, but the definite cause is unknown.[6][12] It is more common in boys than girls.[6][12] Fever is supposedly a risk factor for Febrile Infection-Related Epilepsy Syndrome.[7] As FIRES is an autoimmune disorder, any infection can be activated it.[13] Neuroinflammation can also be observed as one of the underlying causes of FIRES.[10][14]

Diagnosis

FIRES is difficult to diagnose due to its rarity and lack of definitive biomarkers.[11] The diagnosis of FIRES is mostly clinically based due to a lack of identified sources.[11][15] The clinical features consist of remediable and not remediable infections and metabolic causes which help to develop the super-refractory SE, which leads to febrile illness.[13] It is often diagnosed by ruling out other options such as infectious, toxic, metabolic, and genetic causes.[13] FIRES can be misinterpreted as infection encephalitis, this is one of the great reasons for misdiagnosed FIRES.[13] There is no availability of genetic testing or biological markers.[15] The patients presented with a history of febrile illness moistly upper respiratory tract infection, gastroenteritis, etc., and also numerous episodes of seizures (50-10/day), which developed shortly.[15] Hyperacute phase abnormalities can be seen in EEG findings for FIRES.[11]

FIRES can be diagnosed by the below-mentioned examinations:[7]

  • Complete physical examination
  • Thorough medical history evaluation
  • Assessment of signs and symptoms
  • Laboratory tests
  • Imaging studies

Epidemiology

FIRES is a rare disease estimated prevalence of 1-10 per 100,000.[9][7] The mortality and morbidity rate in Febrile infection-related epilepsy syndrome (FIRES) is significantly high.[9] Those who have survived due to the medication therapy have acquired drug-resistant epilepsy and also intellectual disability.[9] Febrile infection-related epilepsy syndrome (FIRES) affected both adults as well as children, but it is more common in children.[16] The consequence of FIRES is unfortunate, the death rate of up to 30%.[15] Among 60%-100% of the children who survived, later develop mild to severe cognitive impairment, learning disabilities.[16] The mortality rate is about 10%-11% in FIRES.[9] Most of the patients died due to sepsis, obstinate status epilepticus, and also hazardous of treatment.[9] The mortality rate in the severe phase is between 10-11%.[9] The major reasons behind the mortality, are uncontrollable SE, limitations, difficulties in treatment, and also sepsis.[9]

Treatment

he clinicians often faced difficulty to treat FIRES using antiepileptic drugs.[17] There is evidence of a very subtle response against anticonvulsant by the patients of FIRES.[18] In some cases, to control the seizures, the patient frequently needs deep sedation with anesthetic drugs.[17] Long-term treatment plan is also necessary for FIRES.[13]

Ketogenic Diet

Ketogenic diet is effective in some cases, with efficacy ranging from 16% to over 85%.[2][19][20] The features of the ketogenic diet are high protein and low carbohydrate.[11] It has a good success rate for those who are suffering from refractory seizures.[11] The effects of the diet are raises of fatty acids, inflection of glycemia, and comparative limitations in calories.[21] Ketogenic diet can work as an anticonvulsant as well as anti-inflammation.[15] If the KD can start early, it would help for effective and long-term management of epilepsy.[15] KD may not only have an anticonvulsant effect (e.g., through the production of decanoic acid which induces a direct inhibition of the post-synaptic excitatory AMPA) but also anti-inflammatory.[7] Early introduction of a KD could be effective not only during the acute phase but also in long-term epilepsy management.[7]

Vegus Nerve Stimulation

Vagus nerve stimulation helps control seizure activity after recovery from the status.[11] Vagus nerve stimulation (VNS) supports regulator seizure action after retrieval from SEVagus nerve stimulation (VNS) supports regulator seizure action after retrieval from SE.[11]

Intravenous immunoglobulin

Intravenous immunoglobulin treatment is being explored as an option to treat this form of epilepsy.[22]

Barbiturates

Barbiturates have been shown to be effective in treating status epilepsy.[23]

History

FIRES was named in 2008 by Dr. Andreas van Baalen and colleagues.[24] Previous names include AERRPS (acute encephalitis with refractory, repetitive partial seizures), DESC (Devastating Epilepsy in School-aged Children),[25] and NORSE (New-Onset Refractory Status Epilepticus).[25]

EEG Findings

EEG findings suggest FIRES is a focal process with focal onset seizures. In a 2011 study of 77 FIRES patients, 58 had focal seizures. Of the 58, 50 had secondarily generalizing seizures (seizures that evolve from focal to generalized).[2][26] On a 10-20 scalp electrode EEG, the ictal activity commonly begins temporally and spreads hemispherically and/or bilaterally.[27] Interictally, patients may have slowing that may be considered an encephalopathic pattern.[28] A recent study of 12 FIRES patients demonstrated diffuse delta-theta background slowing interictally in all 12 cases.[29]

References

  1. Hirsch, LU; Gaspard, N; van Baalen, A; Nabbout, R; Demeret, S; Loddenkemper, T; Navarro, N; Specchio, N; Lagae, L; Rossetti, A; Hocker, S; Gofton, TE; Abend, NS; Gilmore, EJ; Hahn, C; Khosravani, H; Rosenow, F; Trinka, E (April 2018). "Proposed consensus definitions for new‐onset refractory status epilepticus (NORSE), febrile infection‐related epilepsy syndrome (FIRES), and related conditions". Epilepsia. 59 (4): 739–744. doi:10.1111/epi.14016. PMID 29399791. S2CID 4495659.
  2. Kramer, U; Chi, CS; Lin, KL; Specchio, N; Sahin, M; Olson, H; Nabbout, R; Kluger, G; Lin, JJ; van Baalen, A (November 2011). "Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children". Epilepsia. 52 (11): 1956–65. doi:10.1111/j.1528-1167.2011.03250.x. PMID 21883180.
  3. van Baalen, A; Häusler, M; Plecko-Startinig, B; Strautmanis, J; Vlaho, S; Gebhardt, B; Rohr, A; Abicht, A; Kluger, G; Stephani, U; Probst, C; Vincent, A; Bien, CG (August 2012). "Febrile infection-related epilepsy syndrome without detectable autoantibodies and response to immunotherapy: a case series and discussion of epileptogenesis in FIRES". Neuropediatrics. 43 (4): 209–16. doi:10.1055/s-0032-1323848. PMID 22911482.
  4. "Febrile infection-related epilepsy syndrome - About the Disease - Genetic and Rare Diseases Information Center". rarediseases.info.nih.gov.
  5. "FEBRILE INFECTION RELATED EPILEPSY". www.epilepsydiagnosis.org.
  6. Appenzeller, S; Helbig, I; Stephani, U; Häusler, M; Kluger, G; Bungeroth, M; Müller, S; Kuhlenbäumer, G; van Baalen, A (December 2012). "Febrile infection-related epilepsy syndrome (FIRES) is not caused by SCN1A, POLG, PCDH19 mutations or rare copy number variations". Developmental Medicine and Child Neurology. 54 (12): 1144–8. doi:10.1111/j.1469-8749.2012.04435.x. PMID 23066759. S2CID 19954159.
  7. "Febrile Infection-Related Epilepsy Syndrome". DoveMed.
  8. Culleton, S; Talenti, G; Kaliakatsos, M; Pujar, S; D'Arco, F (April 2019). "The spectrum of neuroimaging findings in febrile infection-related epilepsy syndrome (FIRES): A literature review". Epilepsia. 60 (4): 585–592. doi:10.1111/epi.14684. PMID 30854647. S2CID 73726642.
  9. Payne, ET; Koh, S; Wirrell, EC (April 2020). "Extinguishing Febrile Infection-Related Epilepsy Syndrome: Pipe Dream or Reality?". Seminars in Neurology. 40 (2): 263–272. doi:10.1055/s-0040-1708503. PMID 32185792. S2CID 212750609.
  10. Sakuma, H; Horino, A; Kuki, I (June 2020). "Neurocritical care and target immunotherapy for febrile infection-related epilepsy syndrome". Biomedical Journal. 43 (3): 205–210. doi:10.1016/j.bj.2020.03.009. PMC 7424090. PMID 32330681.
  11. Hon, KL; Leung, AKC; Torres, AR (2018). "Febrile Infection-Related Epilepsy Syndrome (FIRES): An Overview of Treatment and Recent Patents". Recent Patents on Inflammation & Allergy Drug Discovery. 12 (2): 128–135. doi:10.2174/1872213X12666180508122450. PMID 29745347. S2CID 13695489.
  12. van Baalen, A; Häusler, M; Boor, R; Rohr, A; Sperner, J; Kurlemann, G; Panzer, A; Stephani, U; Kluger, G (July 2010). "Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood". Epilepsia. 51 (7): 1323–8. doi:10.1111/j.1528-1167.2010.02535.x. PMID 20345937. S2CID 27421912.
  13. van Baalen, A; Vezzani, A; Häusler, M; Kluger, G (February 2017). "Febrile Infection-Related Epilepsy Syndrome: Clinical Review and Hypotheses of Epileptogenesis". Neuropediatrics. 48 (1): 5–18. doi:10.1055/s-0036-1597271. PMID 27919115.
  14. van Baalen, A; Häusler, M; Plecko-Startinig, B; Strautmanis, J; Vlaho, S; Gebhardt, B; Rohr, A; Abicht, A; Kluger, G; Stephani, U; Probst, C; Vincent, A; Bien, CG (August 2012). "Febrile infection-related epilepsy syndrome without detectable autoantibodies and response to immunotherapy: a case series and discussion of epileptogenesis in FIRES". Neuropediatrics. 43 (4): 209–16. doi:10.1055/s-0032-1323848. PMID 22911482.
  15. Serino, D; Santarone, ME; Caputo, D; Fusco, L (2019). "Febrile infection-related epilepsy syndrome (FIRES): prevalence, impact and management strategies". Neuropsychiatric Disease and Treatment. 15: 1897–1903. doi:10.2147/NDT.S177803. PMC 6635824. PMID 31371963.
  16. Fox, K; Wells, ME; Tennison, M; Vaughn, B (2017). "Febrile Infection-Related Epilepsy Syndrome (FIRES): A Literature Review and Case Study". The Neurodiagnostic Journal. 57 (3): 224–233. doi:10.1080/21646821.2017.1355181. PMID 28898171. S2CID 8944135.
  17. Lam, SK; Lu, WY; Weng, WC; Fan, PC; Lee, WT (June 2019). "The short-term and long-term outcome of febrile infection-related epilepsy syndrome in children". Epilepsy & Behavior. 95: 117–123. doi:10.1016/j.yebeh.2019.02.033. PMID 31035103. S2CID 134192429.
  18. Meenakshi-Sundaram, S; Sankaranarayanan, M; Jeyaraman, M; Ayyappan, C; Karthik, SN; Pandi, S (March 2021). "Super refractory status in a case of Febrile Infection-Related Epilepsy Syndrome due to hemophagocytic lymphocytic histiocytosis". Epilepsia Open. 6 (1): 22–27. doi:10.1002/epi4.12454. PMC 7918320. PMID 33681644.
  19. Sonkodi, S; Dobozy, A; Tichy, B; Mágori, A; Boda, K; Ormos, J (1984). "Inhibiting effect of foetal renal antigen on leukocyte migration in human glomerulonephritis". International Urology and Nephrology. 16 (2): 175–80. doi:10.1007/BF02082782. PMID 6469483. S2CID 23917498.
  20. Nabbout, R; Mazzuca, M; Hubert, P; Peudennier, S; Allaire, C; Flurin, V; Aberastury, M; Silva, W; Dulac, O (October 2010). "Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES)". Epilepsia. 51 (10): 2033–7. doi:10.1111/j.1528-1167.2010.02703.x. PMID 20813015.
  21. Koh, S; Dupuis, N; Auvin, S (November 2020). "Ketogenic diet and Neuroinflammation". Epilepsy Research. 167: 106454. doi:10.1016/j.eplepsyres.2020.106454. PMID 32987244. S2CID 221501640.
  22. Gall, C.R.E., Jumma, O. & Mohanraj, R. 2013, "Five cases of new onset refractory status epilepticus (NORSE) syndrome: Outcomes with early immunotherapy", Seizure, vol. 22, no. 3, pp. 217-220
  23. Pranzatelli, M.R. & Nadi, N.S. 1995, "Mechanism of action of antiepileptic and antimyoclonic drugs.", Advances in Neurology, vol. 67, pp. 329-360.
  24. van Baalen, A; Häusler, M; Boor, R; Rohr, A; Sperner, J; Kurlemann, G; Panzer, A; Stephani, U; Kluger, G (July 2010). "Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood". Epilepsia. 51 (7): 1323–8. doi:10.1111/j.1528-1167.2010.02535.x. PMID 20345937. S2CID 27421912.
  25. Simon Shorvon and Monica Ferlisi (2011-09-13). "The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol". Brain. Brain.oxfordjournals.org. 134 (Pt 10): 2802–2818. doi:10.1093/brain/awr215. PMID 21914716.
  26. Fox, Kristy; Wells, Mary Ellen; Tennison, Michael; Vaughn, Bradley (July 11, 2017). "Febrile Infection-Related Epilepsy Syndrome (FIRES): A Literature Review and Case Study". The Neurodiagnostic Journal. 57 (3): 224–233. doi:10.1080/21646821.2017.1355181. PMID 28898171. S2CID 8944135.
  27. Howell, KB; Katanyuwong, K; Mackay, MT; Bailey, CA; Scheffer, IE; Freeman, JL; Berkovic, SF; Harvey, A (2012). "Long-term follow-up of febrile infection-related epilepsy syndrome". Epilepsia. 53 (1): 101–110. doi:10.1111/j.1528-1167.2011.03350.x. PMID 22191582. S2CID 9165846.
  28. Nabbout, R; Vezzani, A; Dulac, O; Chiron, C (2011). "Acute encephalopathy with inflammation-mediated status epilepticus". Lancet Neurol. 10 (1): 99–108. doi:10.1016/S1474-4422(10)70214-3. PMID 21163447. S2CID 206159592.
  29. Carabello, RH; Reyes, G; Avaria, MF; Buompadre, MC; Gonzalez, M; Fortini, S; Cersosimo, R (2013). "Febrile infection related epilepsy syndrome: a study of 12 patients". Seizure. 22 (7): 553–559. doi:10.1016/j.seizure.2013.04.005. PMID 23643626. S2CID 14416943.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.